Monitoring trends in the absolute lymphocyte count and the neutrophil-to-lymphocyte ratio in patients with breast cancer receiving eribulin.

Moreover, a decreasing trend for NLR at 1 month after eribulin initiation showed no significant association with better PFS compared with a non-decreasing trend ( p = 0.051, Fig. 1 F).

also in 47,180 other papers

This finding is consistent with a previous study that indicated an increasing trend in the NLR after six cycles of bevacizumab was linked to a higher mortality risk in patients with advanced non-small cell lung cancer [ 20 ].

also in 63,971 other papers